Image Source: AsiaOne
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan GlobeNewswire August 07, 2020 Novavax will license COVID-19 vaccine technology to Takeda for local production and commercialization in JapanMatrix-M adjuvant to be supplied from NovavaxGovernment of Japan will provide funding to Takeda for technology transfer, establishment of infrastructure and scale-up of manufacturingAdds to Takeda’s ongoing support of influenza pandemic preparedness in JapanGAITHERSBURG, Md. and OSAKA, Japan, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan.
Source: AsiaOne